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Abstract
Background: Cigarette smoking is the most established risk factor, and genetic variants and/or gene promoter
methylations are also considered to play an essential role in development of lung cancer, but the pathogenesis of
lung cancer is still unclear.
Methods: We collected the data of 150 cases and 150 age-matched and sex-matched controls on a Hospital-Based
Case-Control Study in China. Face to face interviews were conducted using a standardized questionnaire. Gene
polymorphism and methylation status were measured by RFLP-PCR and MSP, respectively. Logistic regressive
model was used to estimate the odds ratios (OR) for different levels of exposure.
Results: After adjusted age and other potential confounding factors, smoking was still main risk factor and
significantly increased 3.70-fold greater risk of NSCLC as compared with nonsmokers, and the ORs across increasing
levels of pack years were 1, 3.54, 3.65 and 7.76, which the general dose-response trend was confirmed. Our striking
findings were that the risk increased 5.16, 8.28 and 4.10-fold, respectively, for NSCLC with promoter
hypermethylation of the p16, DAPK or RARb gene in smokers with CYP1A1 variants, and the higher risk significantly
increased in smokers with null GSTM1 and the OR was 17.84 for NSCLC with p16 promoter hypermethylation, 17.41
for DAPK, and 8.18 for RARb in smokers with null GSTM1 compared with controls (all p < 0.01).
Conclusion: Our study suggests the strong combined effects of cigarette smoke, CYP1A1 and GSTM1
Polymorphisms, hypermethylations of p16, DAPK and RARb promoters in NSCLC, implying complex pathogenesis of
NSCLC should be given top priority in future research.
Background
Lung cancer kills over one million people each year all
over the world, and it is a major public health problem
as the leading cause of cancer death in men and second
leading cause in women [1]. The two major forms of
lung cancer are non-small cell lung cancer (NSCLC,
about 85% of all lung cancer) which includes squamous
cell carcinoma, adenocarcinoma and large cell carci-
noma, and small-cell lung cancer (SCLC, about 15%)[2].
Lung cancer mortality has increased rapidly during
recent years in Asian countries as the use of tobacco
products is increasing [3]. About 80-90% of lung cancers
are attributable to cigarette smoking, and an estimated
20% of all lung cancers are caused by a combination of
environmental and/or genetic factors [4], but inter-indi-
vidual differences in carcinogen metabolism may play an
essential role in the initiation and progression of this
environmental cancer and affect individual susceptibility
to lung cancer [5,6]. Cigarette tobacco contains a variety
of carcinogens, such as polycyclic aromatic hydrocar-
bons(PAHs), N-nitrosoamines, and aromatic heterocyclic
amines [7]. PAHs are metabolized to reactive DNA
binding diols epoxides by phase I (e.g. CYP1A1)a n d
detoxified by phase II (e.g. GSTM1) before targeting
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bolic activities in each phase or both phases of metabo-
lism coordinately modulate the clearance of DNA [8].
Many studies have reported that polymorphism in
CYP1A1 as well as in GSTM1, or combination effect of
both, have been associated with different types of cancer
risk including human lung cancer [9].
It is now recognized that not only genetic mechan-
isms, such as gross chromosomal alterations or single
nucleotide mutations, but also aberrant DNA methyla-
tion provides one or both of the two hits postulated in
Knudson’s two hit hypothesis for the inactivation of
tumor suppressor genes. Many studies have indicated
that aberrant methylation of the promoter causes tran-
scriptional silencing of some important suppressor
genes, such as cell cycle gene p16, apoptosis gene
DAPK, cell differentiation and proliferation gene RARb,
DNA repair gene MGMT, and this has been implicated
in the carcinogenic process in human lung cancer [4].
Furthermore, methylation has been described as an early
event in lung tumorigenesis and variation in methylation
status has been associated with cigarette smoke expo-
sure [10,11]. In addition, only a relative small study has
examined the relationship between polymorphisms in
XRCC1, GSTM1, GSTP1, NQO1, and MPO and aberrant
methylation of p16, RARb and MGMT in lung cancer
[6]. Those result suggested that GSTP1 and NQO1 var-
iations increased the risk of MGMT methylation, and
the possibility of p16 and RARb methylations was
increased for XRCC1 and MPO gene polymorphisms,
indicating the interactions between gene polymorphisms
and aberrant methylation of tumor suppress genes.
Above facts led us hypothesize that major metabolic
enzyme gene genetic polymorphisms and environmental
factors, such as cigarette smoking and diet habits, may
interact during the hypermethylations of tumor suppres-
sor gene (TSG) promoters in the carcinogenesis of
NSCLC. So, the present study have mainly investigated
the association between cigarette smoking, polymorph-
isms of CYP1A1 and GSTM1 genes, hypermethylations
of p16, DAPK and RARb gene promoters in NSCLC.
Methods
Study population
150 individuals with NSCLC and 150 age-matched
(within 3 years) and sex-matched controls were enrolled
in this study from June 2005 to December 2007 at 1
stAf-
filiated hospital of Anhui Medical University, China. Of
patients with lung cancer, histological subtype including
83 squamous cell carcinomas, 33 adenocarcinomas and
34 mixed types of both were confirmed. 57 patients had
stage I disease, 64 patients had stage II disease, 20
patients had stage III A disease, 5 patients had stage III
B disease, and 4 patients had stage IV disease. Controls
were selected from patients newly diagnosed with dis-
eases other than cancer and chronic respiratory diseases
or from individuals receiving routine medical examina-
tions at the same hospitals. There were no significant
difference of mean age between cases and controls
(59.81 ± 9.18 vs 59.91 ± 8.71 years). There were 125
males and 25 females in cases or controls group. This
study was approved by the Ethical Committee of Anhui
Medical University and conducted in accordance with
the recommendations outlined in the Declaration of
Helsinki, and all subjects provided written informed
consent.
Exposure to environmental factors
Trained interviewers used a structured questionnaire to
interview each subject face to face when the subjects
agreed to take part in this study and underwent medical
examination. The questionnaire mainly included ques-
tions on demographic factors, smoking history (duration
and daily consumption of cigarettes), consumption of
alcohol, tea drinking and dietary factors (i.e. intake of
peppery and/or fruit), family history of cancer in first
relatives (i.e., parents, siblings and offspring), and clini-
cal features of lung cancer and complete medical his-
tory. Smoking habit was defined as smoking more than
1 cigarette a day for at least 1 year, or more than 360
cigarettes a year. Pack years were calculated by multiply-
ing the number of packs of cigarettes smoked a day by
the number of years the person had smoked. Alcohol
habit was defined as drinking more than twice a week,
consumption of more than 50 ml of heavy liquor or 500
ml of beer on each occasion. Tea habit was defined as
drinking tea at least one time a day for at least 1 year.
The servings of peppery or fruit was defined to intake
more than twice a week.
DNA extraction and genotyping
Cases and controls were asked to provide 5 ml periph-
eral venous blood. This was separated in two aliquots of
1 ml serum and in two aliquots of buffy coats and
stored at -20°C. Genomic DNA was extracted from the
buffy coats using QIA Gen Blood Kit according to the
manufacture’s instructions (Qiagen). A DyNA Quant
200 fluormeter (Hoefer, San Francisco, CA) was used to
test DNA concentration. CYP1A1 (MspI) polymorphism
and GSTM1 deletion were measured by RFLP-PCR on
ABI 9600 Thermal Cycler. Table 1 showed the main
parameters of PCR.
Methylaiton-specific PCR for p16, DAPK and RARb
promoters
Primary tumor and corresponding nonmalignant lung
tissue samples (n = 150, separately) were obtained from
NSCLC patients who had been treated with curative
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st Affiliated hospital of Anhui
Medical University between June 2005 and December
2007. Those samples were snap-frozen in liquid nitrogen
and stored at -70°C until genomic DNA preparation.
Genomic DNA was extracted using QIA tissue kitac-
cording to the manufacturer’s instructions (Qiagen). A
DyNA Quant 200 fluorometer (Hoefer, San Francisco,
CA) was used to measure DNA concentration.
Methylation status of the promoter region of the p16,
DAPK and/or RARb was determined by MSP described
by Zochbauer-Muller et al. [12]. Two sets of primers
were designed, one specific for DNA methylated at the
promoter region of each gene and the other specific for
unmethylated DNA (Table 2). Amplification was carried
out on ABI 9600 Thermal Cycler.
Data analysis
To determine the association between each of the test
genes and lung cancer, the homozygous (AA or aa gen-
otype) and heterozygous (Aa genotype) states of the var-
iants were first analyzed as categorical variables, and
then reanalyzed as dichotomized variables grouped by
the risk genotype (i.e., 0 for the wild type homozygous,
and 1 for the other genotypes combined). To evaluate
the effects of combined genotypes, environmental fac-
tors either together or separately, subjects were categor-
ized into homozygous wild type, and possession of one
or more of the risk genotypes (heterozygous + homozy-
gous for the variant). Compared with the wild type gen-
otype, the odds ratio (OR) and 95% confidence interval
(CI) of the various genotypes was calculated for lung
cancer risks in univariate analysis model. Multivariate
logistic regression was conducted to estimate the rela-
tionship between smoking, polymorphisms of metabolic
enzyme genes and methylation inactivate of tumor sup-
pressor genes in NSCLC after adjusted the potential
confound factors. SAS software (version 9.1; SAS Insti-
tute, Inc.) was used for statistical analysis, using the x
2
and Fisher’s exact test for differences between groups
and t tests between means. All tests were two-sided, and
a p value of <0.05 for any test or models was considered
statistically significant.
Results
The ORs of major risk factors among cased and controls
are shown in Table 3. After adjusting for potential con-
founders, there were no significant differences between
the cases and controls in alcohol habit, tea habit, dust
exposure (≥1 month/year), toxin exposure (≥1m o n t h /
year), and the family history of lung cancer among first
relatives of patients. Genotype frequencies for CYP1A1
and GSTM1 are calculated, which these distributions are
consistent with the Hardy-Weinberg equilibrium model.
In the control group, the allele frequency for MspI was
0.30 (a), whereas that for lung cancer group was 0.29. A
non-significant difference was observed between cases
and controls. In addition, 53% of controls and 63% of
cases were homozygous for null variant allele of
GSTM1. No significant associations between the variants
of CYP1A1 or GSTM1 and lung cancer. However, signif-
icant associations were also found between lung cancer
and the follow variables: smoking habit, pack years, pep-
pery (servings, > 2 times/week), and fruit (servings, > 2
times/week) (Table 3).
Table 1 Summary of primer sequences, annealing temperatures and PCR product sizes used for CYP1A1 (MspI) and
GSTM1
Gene Primer °C bp
CYP1A1 (MspI) Forward 5’-CAGTGAAGAGGTGTAGCCGCT-3’ 60 340
Reverse 5’-TAGGAGTCTTGTCTCATGCCT-3’
GSTM1 Forward 5’-GAACTCCCTGAAAAGCTAAAGC-3’ 59 215
Reverse 5’-GTTGGGCTCAAATATACGGTG G-3’
b-Globin (reference) Forward 5’-CAACTTCATCCACGTTCACC-3’ 59 268
Reverse 5’-GAAGAGCCAAGGACAGGTA-3’
Table 2 Summary of primer sequences*, annealing temperatures, and PCR product sizes used for MSP
Gene Forward primer (5’ -3 ’) Reverse primer (3’ -5 ’) Tm (°C) Size (bp)
p16 M: TTATTAGAGGGTGGGGCGGATCGC** M: GACCCCGAACCGCGACCGTAA 60 150
U: TTATTAGAGGGTGGGGTGGATTGT U: CAACCCCAAACCACAACCATAA 60 151
DAPK M: GGATAGTCGGATCGAGTTAACGTC M: CCCTCCCAAACGCCGA 59 98
U: GGAGGATAGTTGGATTGAGTTAATGTT U: CAAATCCCTCCCAAACACCAA 59 106
RARb M: TCGAGAACGCGAGCGATTCG M: GACCAATCCAACCGAAACGA 56 146
U: TTGAGAATGTGAGTGATTTGA U: AACCAATCCAACCAAAACAA 56 146
* Reference for primer sequences: Ref. [13].
** M. methylated-specific primers: U. unmethylated-specific primers.
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tor of lung cancer, and increased 3.70 times greater risk
of NSCLC compared with nonsmoker. Further, the OR
of NSCLC increased with higher categories of total
smoking pack year, from 3.54 in the second category to
7 . 7 6i nt h ef o u r t hc a t e g o r y( T a b l e3 ) .O R so ft h et h r e e
higher categories were all statistically significant. After
adjustment for the potential confounding factors in the
multivariate analysis models, ORs in each category of
smoking pack years increased, and CIs became wider,
but the general dose-response trend was maintained
(Table 3). Interestingly, we found the preventive effects
of peppery or fruit servings on lung cancer, and OR was
0.35 (95%CI, 0.16-0.76) and 0.16 (95%CI, 0.06-0.43),
respectively. This study suggested non-significant asso-
ciation of variants of CYP1A1 and GSTM1 with NSCLC
alone or in combination. However, the risk increased
about 4-fold in smokers with CYP1A1 variants as com-
pared with CYP1A1 wild homozygous non-smokers and
7-fold when smokers having null GSTM1 were com-
pared with power GSTM1 non-smokers. These results
can imply the interactions of smoking and the genetic
variants of CYP1A1 and GSTM1 in NSCLC (Table 4).
We used MSP to determine the frequency of methyla-
tion of p16, DAPK and RARb in 150 resected NSCLCs,
which was 48.67%, 58.67% and 60.00%, respectively. In
the corresponding nonmalignant lung tissues, it was seen
at low frequencies for p16 (9.93%), DAPK (9.93%) and
RARb (17.02%). Those indicated the significant difference
between lung cancer tissues and nonmalignant lung tis-
sue in methylations of three genes. In addition, we found
that at least one of these three genes had methylation in
85.33% of the tumors; 26% of the tumors had only one
gene methylated, 36.67% of the tumors had two genes
methylated and 22.67% of the tumors had three genes
methylated. A statistically significant corrrlation was
found for the methylation status between p16 and DAPK
(p = 0.0006), whereas the methylation status of the other
genes was independent when compared with each other.
Although no association was apparent among the
CYP1A1 or GSTM1 polymorphisms and p16, DAPK or
RARb promoter methylation, GSTM1 null genotype was
significantly associated with at least one methylation
among p16, DAPK and RARb genes (OR, 1.67; 95% CI,
1.01-2.77) (no data shown).
Table 5 presents OR estimates for smoking habits,
pack years, diet habits, family history of lung cancer,
and polymorphisms of CYP1A1 and GSTM1 as com-
pared with controls according to the cases with or with-
out promoter hypermethylation of the p16, DAPK or
RARb gene. Obviously, smoking habits increased the
risk of NSCLC with promoter hypermethylation of the
p16, DAPK or RARb, which OR is 4.56, 3.83, 3.11,
respectively. As the amount of pack years increased, the
risk of NSCLC with promoter hypermethylation of the
p16, DAPK or RARb gene was greater, indicating a
graded positive association between both. The results
may also imply the interaction between cigarette smok-
ing and promoter hypermethylation of the p16, DAPK
or RARb gene in NSCLC. In addition, a possible associa-
tion was found between null GSTM1 and NSCLC with
promoter hypermethylation of the DAPK or RARb gene,
Table 3 ORs of major risk factors for non-small cell lung cancer.
Factor Crude risk Adjusted risk
OR 95% CI p-value OR
a 95% CI p-value
Smoking habit(yes/no) 2.21 1.35-3.3.63 <0.01 3.70 1.49-9.19 p < 0.01
Pack years <20 1.00 - - 1.00 - -
20-30 3.27 1.43-7.49 <0.01 3.54 1.11-11.26 p < 0.05
30-40 3.53 1.72-7.26 <0.01 3.65 1.27-10.50 p < 0.05
≥40 7.54 3.95-14.41 <0.01 7.76 3.00-20.11 p < 0.01
x
2 test for trend p < 0.001 p < 0.001
Alcohol habit(yes/no) 1.46 0.92-2.30 >0.05 1.72 0.83-3.53 p > 0.05
Tea habit(yes/no) 1.14 0.69-1.89 >0.05 0.92 0.41-2.09 p > 0.05
Peppery (servings, > 2 times/week, yes/no) 0.61 0.38-0.98 <0.05 0.35 0.16-0.76 p < 0.01
Fruit (servings, > 2 times/week, yes/no) 0.28 0.14-0.58 <0.01 0.16 0.06-0.43 p < 0.01
Dust exposure
b (yes/no) 3.55 2.08-6.04 <0.01 2.06 0.93-4.57 p > 0.05
Toxin exposure
b (yes/no) 1.31 0.79-2.18 >0.05 0.68 0.30-1.56 p > 0.05
Lung cancer in firstdegree relatives (yes/no) 1.35 0.63-2.88 >0.05 1.44 0.41-5.06 p > 0.05
CYP1A1((Aa + aa)/AA)
c 1.03 0.65-1.62 >0.05 0.83 0.42-1.65 p > 0.05
GSTM1(null/power)
d 1.55 0.98-2.46 >0.05 1.13 0.57-2.24 p > 0.05
a adjusted for sex, age, alcohol habit, tea habit, smoking habit and history of lung cancer in first-degree relatives.
b cumulative exposure ≥3 months/year or continuous exposure ≥1 months/year.
c AA = homogeneity wild genotype, Aa = heterogeneity genotype, aa = homogeneity variant genotype
d - = null type, + = power
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Factor Case(n) Control(n) Crude OR (95% CI) Adjusted OR
a (95% CI)
CYP1A1
b GSTM1
c
Aa+aa - 43 39 1.63(0.81-3.31) 1.67(0.85-3.29)
+ 28 31 1.34(0.62-2.89) 1.55(0.74-3.25)
AA - 52 40 1.93(0.97-3.84) 2.03(1.04-3.94)*
+ 27 40 1.00(reference) 1.00(reference)
Smoking habit CYP1A1
Yes Aa+aa 52 39 2.37(1.10-5.15)* 3.72(1.56-8.86)**
AA 61 48 2.26(1.07-4.78)* 3.47(1.47-8.16)**
No Aa+aa 19 31 1.09(0.45-2.66) 1.08(0.47-2.51)
AA 18 32 1.00(reference) 1.00(reference)
Smoking habit GSTM1
Yes - 70 51 4.00(1.79-9.09)** 6.76(2.62-17.46)**
+ 43 36 3.48(1.48-8.33)** 5.93(2.26-15.59)**
No - 25 28 2.60(1.03-6.67)* 2.84(1.17-6.92)*
+ 12 35 1.00(reference) 1.00(reference)
a adjusted for sex, age, alcohol habit, tea habit, smoking habit and history of lung cancer in first-degree relatives.
b AA = homogeneity wild genotype, Aa = heterogeneity genotype, aa = homogeneity variant genotype
c - = null type, + = power
*p<0 . 0 5* *p<0 . 0 1
Table 5 The interactions between cigarette smoking, genetic variants of CYP1A1and GSTM1, and promoter
hypermethylations of the p16, DAPK and RARb genes in non-small cell lung cancer
Factor OR
a (95% CI)
Cases with TSG
b promoter hypermethylation Cases without TSG promoter hypermethylation
p16 DAPK RARb p16 DAPK RARb
Smoking habit (yes/no) 4.56** 3.83** 3.11** 1.34 1.23 1.45
(2.17-9.58) (1.99-7.38) (1.67-5.78) (0.76-2.37) (0.67-2.26) (0.77-2.71)
Pack years
<20 1.00 1.00 1.00 1.00 1.00 1.00
(reference) (reference) (reference) (reference) (reference) (reference)
20-29 4.62** 6.72** 3.27* 2.60 1.23 3.27*
(1.63-13.13) (2.63-17.18) (1.23-8.69) (0.99-6.80) (0.37-4.12) (1.19-9.01)
30-39 5.08** 6.82** 4.27** 1.75* 1.58 2.70*
(2.04-12.69) (2.2.94-15.81) (1.88-9.70) (1.19-6.36) (0.59-4.20) (1.06-6.89)
≥40 14.29** 13.50** 9.50** 4.17** 4.01** 5.34**
(6.55-31.18) (6.31-28.89) (4.62-19.53) (1.96-8.88) (1.85-8.68) (2.40-11.88)
x
2 test for trend p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
CYP1A1 ((Aa+aa)/AA)
c 0.97 1.14 1.06 1.07 0.88 0.94
(0.55-1.81) (0.67-1.92) (0.62-1.80) (0.61-1.86) (0.48-1.59) (0.51-1.71)
GSTM1 (null/power)
d 1.45 1.73* 1.98** 1.67 1.33 1.10
(0.82-2.56) (1.01-2.99) (1.15-3.44) (0.96-2.94) (0.73-2.43) (0.60-2.00)
a adjusted for sex, age, alcohol habit, tea habit, smoking habit and history of lung cancer in first-degree relatives.
b TSG = tumor suppress gene including p16, DAPK and RARb.
c AA = homogeneity wild genotype, Aa = heterogeneity genotype, aa = homogeneity variant genotype
d - = null type, + = power
* p < 0.05, **p < 0.01
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rant methylations of TSG in lung cancer. Of note,
higher consumption of fruit was associated with lower
risk of NSCLC with or without promoter hypermethyla-
tion of the p16, DAPK or RARb gene (no data shown)
(Table 5).
Based on above results, Table 6 considers the interac-
tion between smoking habits, polymorphisms of
CYP1A1 and GSTM1 variants in NSCLC with or with-
out promoter hypermethylations of the p16, DAPK or
RARb gene as compared with controls. We didn’tf o u n d
the interaction between CYP1A1 polymorphisms and
GSTM1 variant in NSCLC with or without promoter
hypermethylation of the p16, DAPK or RARb gene.
Nevertheless, as compared with controls, the risk
increased 5.16, 8.28 and 4.10-fold, respectively, for
NSCLC with promoter hypermethylation of the p16,
DAPK or RARb gene in smokers with CYP1A1 variants
(Aa+aa). Strikingly, the risk strongly increased in smo-
kers with null GSTM1,a n dt h eO Rw a s1 7 . 8 4f o r
NSCLC with p16 promoter hypermethylation, 17.41 for
DAPK, and 8.18 for RARb in smokers with null GSTM1
compared with controls. In contrast, the smokers with
null GSTM1 have lower risk for NSCLC without TSG
promoter hypermethylation. To a certain extent, these
results are in agreement with a previous multiplicative
model for risk combination between smoking habits and
metabolic enzyme gene polymorphisms analyzed when
the cases were not stratified by TSG methylation status.
These results may further confirm the interactions
Table 6 Interactions between cigarette smoking and the genetic variants of CYP1A1 and GSTM1 in non-small cell lung
cancer with or without promoter hypermethylations of the p16, DAPK and RARb genes
Factor OR
a (95% CI)
Cases with TSG
b promoter hypermethylation Cases without TSG promoter hypermethylation
p16 DAPK RARb p16 DAPK RARb
CYP1A1
c GSTM1
d
Aa+aa - 1.41 2.05 2.12* 1.96 1.18 1.03
(0.64-3.08) (0.94-4.47) (0.99-4.52) (0.84-4.59) (0.50-2.81) (0.41-2.56)
+ 0.97 1.48 1.12 1.88 1.19 1.61
(0.40-2.34) (0.63-3.47) (0.47-2.69) (0.76-4.61) (0.48-2.97) (0.66-3.94)
AA - 1.44 2.14* 2.07 2.64* 1.69 1.75
(0.66-3.12) (0.99-4.63) (0.97-4.40) (1.16-5.99) (0.75-3.82) (0.76-4.03)
+ 1.00 1.00 1.00 1.00 1.00 1.00
(reference) (reference) (reference) (reference) (reference) (reference)
Smoking habit CYP1A1
Yes Aa+aa 5.16* 8.28** 4.10** 2.73 1.58 2.82
(1.45-18.35) (2.38-28.75) (1.43-11.76) (0.97-7.64) (0.54-4.68) (0.87-9.16)
AA 4.75* 6.57** 3.50* 2.60 2.16 3.29
(1.35-16.65) (1.91-22.64) (1.22-10.01) (0.95-7.11) (0.77-6.02) (1.07-10.11)
No Aa+aa 0.94 0.85 0.91 1.20 1.39 1.38
(0.24-3.68) (0.25-2.88) (0.31-2.70) (0.47-3.08) (0.52-3.72) (0.48-3.96)
AA 1.00 1.00 1.00 1.00 1.00 1.00
(reference) (reference) (reference) (reference) (reference) (reference)
Smoking habit GSTM1
Yes - 17.84** 17.41** 8.18** 4.43** 2.76 4.69*
(3.10-102.64) (4.21-72.05) (2.53-26.49) (1.54-12.78) (0.88-8.60) (1.29-17.05)
+ 17.62** 12.29** 5.14** 3.09* 3.35* 7.10**
(3.08-100.91) (2.95-51.21) (1.55-17.05) (1.04-9.14) (1.08-10.39) (1.98-25.41)
No - 6.18** 2.81 2.47 2.24 3.00* 3.68*
(1.14-33.56) (0.77-10.20) (0.79-7.72) (0.85-2.90) (1.05-8.55) (1.15-11.77)
+ 1.00 1.00 1.00 1.00 1.00 1.00
(reference) (reference) (reference) (reference) (reference) (reference)
a adjusted for sex, age, alcohol habit, tea habit, smoking habit and history of lung cancer in first-degree relatives.
b TSG = tumor suppress gene including p16, DAPK and RARb
c AA = homogeneity wild genotype, Aa = heterogeneity genotype, aa = homogeneity variant genotype
d - = null type, + = power
* p < 0.05, **p < 0.01
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GSTM1, and promoter hypermethylation of the p16,
DAPK or RARb gene in NSCLC (Table 6).
Discussion
Many epidemiologic studies have demonstrated cigarette
smoking is the major risk factor of lung cancer [13-15],
with a obvious dose-response relationship [16]. Our
findings (OR = 3.70, p < 0.01) supported these results
unquestionably. There are more than 4000 chemical
materials in cigarette smoking, and approximately 200
may be carcinogens, such as aromatic hydrocarbons,
which have proved to cause lung carcinogenesis, and
increasing mortality from lung cancer is closely asso-
ciated with the consumption of tobacco [14]. Although
the majority of lung cancer patients are smokers, only
10-15% of all smokers will develop the disease [17], indi-
cating environmental or genetic determinants in disease
initiation, promotion and progression. Since many carci-
nogens require metabolic activation via phase I enzymes
to enable to react with cellular macromolecules or meta-
bolic detoxification via phase II enzymes to enable to
eliminate from body, inter-individual differences in car-
cinogen metabolism may play a key role in environmen-
tal cancers [4,6]. The most frequently studied phase I
and II enzymes include CYP1A1 and GSTM1.S t u d i e s
from Japanese populations first found an association
between CYP1A1 and polymorphisms and risk of lung
cancer, with reports of >2-fold increased risk [18]. In a
pooled analysis using data from 22 studies, a significant
2.4-fold increased in risk was observed in individuals
carrying the MspI variant [19]. In addition, GSTM1
occurs in the null form in ~50% of the Caucasian popu-
lation. One of the first meta-analyses showed a modest
increase in lung cancer among carriers of the GSTM1-
null genotype (OR = 1.13, 95%CI 1.04-1.25) [20]. The
most recent and large meta-analysis [9] of Chinese
population found that lung cancer risk for CYP1A1 var-
iant was 1.34-fold (95%CI 1.08-1.67, p = 0.008) com-
pared with the wild-type homozygous genotype, and the
risk for the GSTM1 null genotype was 1.54-fold (95%CI
1.31-1.80, p < 0.001) as compared with the GSTM1 pre-
sent genotype. A recent pooled analysis also suggested
that genetic polymorphisms in CYP1A1 and GSTM1 are
associated with lung cancer risk among Asian popula-
tions [3]. Few studies have researched gene-gene inter-
actions in lung cancer. An early study from Japan [18]
reported the combined effects of CYP1A1 MspI geno-
type and deficient GSTM1 in lung cancer (OR = 16.00),
but only at a low-dose level of cigarette smoking. Also,
another analysis indicated a possible interaction between
the CYP1A1*2A allele and GSTM1 deletion on lung can-
cer risk in Caucasians [21]. However, as other studies
have reported conflicting results for CYP1A1 and
GSTM1 polymorphisms in lung cancer [4,6], our study
found neither significant risk of lung cancer for CYP1A1
variants or GSTM1 null genotypes nor possible combi-
nation effects of CYP1A1 and GSTM1 polymorphisms
in the development of lung cancer. The majority of epi-
demiological studies on the effects of low penetrant
genes in cancer etiology have considered main effects
single nucleotide polymorphisms, or gene-environment
interactions and rarely gene-gene interactions, mainly
duo to the lack of statistical power [22]. Most observed
associations between cancer and low penetrant gene var-
iants have been weak or very weak [21]. However, pene-
trance of a gene variant depends on events such as the
interaction with external exposures, with the internal
environment or with other factors (e.g., gene promoter
methylation).
In the present study, the significant interaction
between cigarette smoking and CY1A1 or GSTM1 var-
iants is consistent with the results of previous pooled
analysis that the stronger association between the
CYP1A1 MspI or GSTM1 null and lung cancer was
found among smokers [22], but a non significant ele-
vated risk of interaction between GSTM1 null genotype
and lung cancer was reported among Asian by Benha-
mou and co-workers [23]. Cigarette smoking is known
to be causally related to BPDE-DNA adducts that is ele-
vated in the lung tissue of smokers with GSTM1 null
genotype, which was found to induce mutations in the
hotspot codons of the p53 gene [3,24]. Thus, we specu-
lated that the interaction between CYP1A1 or GSTM1
polymorphisms and lung cancer is related to polycyclic
aromatic hydrocarbons exposure derived from smoking
because polycyclic aromatic hydrocarbons are primarily
metabolized by CYP1A1 and GSTM1. The greater effects
observed among smokers support the smoking-related
etiology of lung cancer in Chinese population.
It is now recognized that not only the inherited varia-
tion in DNA sequence (e.g. gene mutations) but also the
epigenetic events, such as aberrant DNA methylatoin,
both play an essential role in the origination and devel-
opment of lung cancer. The most widely studied epige-
netic event in relation to lung cancer included the
promoter hypermethylation of p16, DAPK or RARb gene
[4,6]. Our findings reported the percentage for p16,
DAPK or RARb methylated was the 48.67%, 58.67% and
60.00% in the tumor tissues of patients with lung cancer,
respectively. Those results were separately a little greater
than other findings that p16 is methylated in ~25-41%
of NSCLC, DAPK in 16-44% and RARb in 40-43%
[25,26], which the differences may mainly result from
ethnic variants. The study examined the relationship
between polymorphisms in CYP1A1 and GSTM1 and
aberrant methylation of p16, DAPK and RARb in lung
cancer. It is the first to found GSTM1 null was
Jin et al. BMC Cancer 2010, 10:422
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and RARb gene promoters (OR = 1.67, 95% CI 1.01-
2.77), supporting interaction between metabolic enzyme
gene polymorphisms and hypermethylation of tumor
suppressor genes in development of NSCLC [27,28].
Also, data from our unconditional logistic models is the
first to show that tobacco smoke play dominant roles in
NSCLC with hypermethylation of p16, DAPK or RARb
promoter, but not without hypermethylation of those
gene promoters. As the amount of cigarette smoking
increased, the risk of NSCLC with p16, DAPK or RARb
promoter hypermethylation increased. To our knowl-
edge, we have first reported the interactions between
smoking and polymorphisms of CYP1A1 and GSTM1
gene were significantly modified by hypermethylation of
p16, DAPK or RARb promoter in NSCLC, indicating the
combined effects of smoking, CYP1A1, GSTM1, p16,
DAPK and RARb gene on development of NSCLC. The
findings suggest that smoking related biological path-
ways leading to the development of lung cancer involve
not only hypermethylations of p16, DAPK and RARb
promoters but also genetic polymorphisms of CYP1A1
and GSTM1 genes. Although it is unclear that environ-
mental factors underlie the targeting of specific gene
promoters for hypermethylation, the characterization of
gene-environment interaction and epigenetic influences
in carcinogenesis is of great importance for preventive
measures such as the setting of exposure threshold
values, public health campaigns and chemopreventive
approaches. Those all need to be further confirmed and
thoroughly studied in different populations.
This study has some strengths and limitations. This is
first study on the interaction between cigarette smoking
and the polymorphisms of CYP1A1 or GSTM1 for
NSCLC with hypermethylations of p16, DAPK and
RARb promoters, which carefully controlled for impor-
tant confounding factors. The selective bias was mostly
controlled by the design of a hospital-based case-control
study. As other case-control studies, this study raises
concern about recall bias and residual confounding. Of
course, the major difficult is still the inability to separate
exposures to factors prior to clinical onset from expo-
sures to factors after clinical onset.
In conclusion, this study confirmed that cigarette
smoking is significantly associated with higher risk of
NSCLC having hypermethylation of p16, DAPK or
RARb promoter, and a general dose-response trend was
confirmed. A striking finding was that the interactions
between smoking and polymorphism of CYP1A1 or
GSTM1 gene increased significantly greater risk of
NSCLC with hypermethylation of p16, DAPK or RARb
promoter, suggesting complex pathogenesis of NSCLC
should be given top priority in future research.
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